Pricing Log in Create free account
Friday 6 November 2026 Export BLLN’s income statement to Excel — free account

BillionToOne, Inc.

BLLN Healthcare Diagnostics & Research

BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.

Revenue
+47.2%
EPS
+164.3%
Free cash flow
+9.25%
Total debt
+60.6%

Quarter to September 2026, against a year earlier

111.96 1.93 −1.69%
Market cap
$5.3B
P/E
88.7×
Fwd P/E
146×
Dividend yield
—
F-score
n/a
Altman Z
6.04
Beneish M
−2.03
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

BillionToOne, Inc. (BLLN) EPS (diluted)

Alert me on EPS (diluted)

BillionToOne, Inc.'s EPS (diluted) for fiscal 2025 was $0.14, compared with −$4.12 in fiscal 2024. Over the twelve months to 30 September 2026 it was $0.92. BillionToOne, Inc. ranks 19th of 49 Diagnostics & Research companies by EPS (diluted).

EPS (diluted), annual

Embed this chart

Annual newest first

Period EPS (diluted) Change
FY2025 $0.14 —
FY2024 −$4.12 —
FY2023 −$8.45 —

Quarterly newest first

Period EPS (diluted) Change
Sep 2026 $0.32 113.33%
Jun 2026 $0.15 (55.88%)
Mar 2026 $0.34 209.09%
Dec 2025 $0.11 10.00%
4 more quarters

EPS (diluted) against peers

Company EPS (diluted)
CDNA CareDx, Inc. compare $2.39
QGEN QIAGEN N.V. compare $1.95
VCYT Veracyte, Inc. compare $1.55
BLLN BillionToOne, Inc. $0.92
SHC Sotera Health Company compare $0.60
NEO NeoGenomics, Inc. compare −$0.25
RDNT RadNet, Inc. compare −$0.27
ADPT Adaptive Biotechnologies Corporation compare −$0.45
GRAL GRAIL, Inc. compare −$9.50

What EPS (diluted) is

Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.

Reported line item

The full definition of EPS (diluted) →

More on BLLN